The 13th annual ADMET conference is returning to London, UK for an in-depth exploration of the optimisation of ADMET modelling techniques, preclinical DMPK applications and the development of biopharmaceuticals. The event will be taking place at the Holiday Inn Kensington Forum on the 9th and 10th July 2018.
An interview with Pau Aceves, Associate Director, Certara Strategic Consulting, has just been released and is available for download on the event website. Mr Aceves will be presenting ‘Applications of PKPD modelling in oncology – an overview’ where he will be discussing binary safety/efficacy endpoints, how patients’ individual characteristics may have as big of an impact as e.g. safety response as solely a dose, how to best manage toxicity, and PK and PKPD time-course describe via a mechanistic model.
Snapshot of Interview with Pau Aceves:
Where do you see the greatest opportunities for ADME-T leaders?
- ‘I see the advent of Machine Learning and Artificial Intelligence as a great opportunity for ADME-T leaders to automatize and increase the productivity and solve nowadays data challenges in R&D. We are nearing a point where human effort alone will no longer be able to process the quantity of data that is being generated. Hence, I believe that the Companies that are able to harness these technologies will become the leaders of drug development in decades to come.’
What are the main challenges in your day-to-day work relating to drug discovery?
- ‘I work mainly in clinical development, so one of my main challenges is the coordination with other drug discovery scientists to ensure that the required data for modelling and simulation are generated during early stages to enable translational PK/PD modelling (i.e. Pop PK/PD, PBPK and QSP).’
This year’s two-day conference will also feature over 15 expert-level speakers from organisations such as AbbVie, Roche, Bayer, GlaxoSmithKline and many more, discussing new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and much more.
To download the full interview, as well as the 2018 agenda and speaker line-up, visit the website at: www.admet-event.com/PR2
________________________________________
Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
________________________________________
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
ADMET
9th – 10th July 2018
Holiday Inn Kensington Forum, London, UK
www.admet-event.com/PR2
Follow us @SMiPharm
#SMiADMET
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk